Immunome, Inc. (NASDAQ:IMNM) Given Average Recommendation of “Buy” by Analysts

Immunome, Inc. (NASDAQ:IMNM) has earned an average recommendation of “Buy” from the seven research firms that are presently covering the company, MarketBeat.com reports. Seven analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have covered the stock in the last year is $28.83.

A number of research analysts recently issued reports on IMNM shares. Wedbush reaffirmed an “outperform” rating and issued a $33.00 price target on shares of Immunome in a report on Monday, January 13th. Stephens began coverage on shares of Immunome in a research note on Friday, November 8th. They issued an “overweight” rating and a $30.00 target price for the company. Finally, Piper Sandler decreased their price target on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th.

Immunome Price Performance

IMNM stock opened at $10.17 on Wednesday. The stock has a market capitalization of $634.81 million, a price-to-earnings ratio of -1.25 and a beta of 1.90. The business has a fifty day moving average price of $11.36 and a 200 day moving average price of $12.89. Immunome has a fifty-two week low of $8.97 and a fifty-two week high of $30.96.

Insider Activity at Immunome

In related news, CTO Philip Tsai acquired 21,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 21st. The stock was acquired at an average cost of $9.43 per share, with a total value of $198,030.00. Following the completion of the purchase, the chief technology officer now directly owns 21,000 shares in the company, valued at approximately $198,030. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Clay B. Siegall bought 66,057 shares of the business’s stock in a transaction on Thursday, November 21st. The stock was bought at an average cost of $9.54 per share, for a total transaction of $630,183.78. Following the purchase, the chief executive officer now directly owns 485,693 shares of the company’s stock, valued at approximately $4,633,511.22. This trade represents a 15.74 % increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 102,862 shares of company stock worth $978,045 over the last ninety days. Company insiders own 8.60% of the company’s stock.

Institutional Trading of Immunome

A number of institutional investors and hedge funds have recently modified their holdings of IMNM. FMR LLC boosted its stake in Immunome by 0.3% during the 3rd quarter. FMR LLC now owns 4,224,700 shares of the company’s stock worth $61,765,000 after acquiring an additional 13,757 shares during the last quarter. Janus Henderson Group PLC boosted its position in shares of Immunome by 10.3% during the third quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock worth $50,971,000 after purchasing an additional 324,614 shares in the last quarter. Marshall Wace LLP boosted its position in shares of Immunome by 228.5% during the second quarter. Marshall Wace LLP now owns 1,713,325 shares of the company’s stock worth $20,731,000 after purchasing an additional 1,191,774 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Immunome by 13.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company’s stock valued at $17,657,000 after buying an additional 144,557 shares during the period. Finally, Victory Capital Management Inc. increased its position in shares of Immunome by 48.1% in the 3rd quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock valued at $10,684,000 after buying an additional 237,497 shares in the last quarter. 44.58% of the stock is owned by institutional investors.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.